N/A
Completed N=4,078
Tele-Pharmacy Intervention to Improve Treatment Adherence
Source: ClinicalTrials.gov NCT02512276 ↗Enrolled (actual)
4,078
Serious AEs
—
Results posted
Jun 2019
Primary outcomePrimary: Medication Adherence — 46.2; 42.1 percentage of days covered
Summary
The purpose of this cluster randomized controlled trial is to evaluate whether a novel tele-pharmacist-based intervention for patients with hyperlipidemia, hypertension, and diabetes improves medication adherence, disease control, and patients' understanding of their treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Medication Adherence |
46.2; 42.1 | — |
| SECONDARY Disease Control - All Eligible Conditions |
67.4; 66.2 | — |
| SECONDARY Disease Control |
72.9; 71.2 | — |
| SECONDARY Healthcare Utilization - ER Visits |
90; 113 | — |
| SECONDARY Healthcare Utilization - Office Visits |
641; 594 | — |
| SECONDARY Healthcare Utilization - Hospitalizations |
170; 156 | — |
Eligibility Criteria
Inclusion Criteria
- Filled and poorly adherent (defined as a PDC < 80%) to medication for hyperlipidemia, hypertension, or diabetes
- Suboptimal average adherence to all of the qualifying medications that a patient has filled (defined as combined (average of averages) PDC < 80%)
- For patients with hypertension or diabetes, poor or worsening disease control (according to relevant clinical targets)
Exclusion Criteria
- Patients with <6 months of continuous enrolment in the health plan
- Patients with no available contact information
Data sourced from ClinicalTrials.gov (NCT02512276). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.